Sanofi: positive results for Libtayo in lung cancer
(CercleFinance.com) - Sanofi unveils the presentation of positive results in phase III for treatment associating Libtayo, a drug developed with Regeneron, with chemotherapy during the 2021 virtual congress of the European Society for Medical Oncology (ESMO).
The test, which assessed Libtayo in patients with metastatic or locally advanced non-small cell lung cancer, achieved its primary endpoint of overall survival, and all the secondary endpoints.
No new safety issues were identified in this product. These results will form the basis for the regulatory applications to be presented in particular in the United States and European Union.
Copyright (c) 2021 CercleFinance.com. All rights reserved.